Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
33 hedge funds and large institutions have $7.64M invested in Repros Therapeutics Inc. in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 8 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
17% less capital invested
Capital invested by funds: $9.16M → $7.64M (-$1.52M)
23% less funds holding
Funds holding: 43 → 33 (-10)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$964K |
| 2 |
AIA
Allegis Investment Advisors
Idaho Falls,
Idaho
|
+$27.1K |
| 3 |
Renaissance Technologies
New York
|
+$13.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.27K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$250K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$192K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$107K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$89.8K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$68K |
RPRX Hedge Fund Activity: Q1 2017 in Review
33 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q1 2017, worth a combined $7.64M — down 17% from $9.16M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RPRX and 2 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 13 added.
The largest buyer was BlackRock, opening a new position worth an estimated $964K. The largest seller was Sphera Funds Management, cutting an estimated $250K.
- 33 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q1 2017, down from 43 in Q4 2016.
- Funds reported $7.64M of Repros Therapeutics Inc. stock for Q1 2017, down 17% quarter-over-quarter.
- 2 funds opened new Repros Therapeutics Inc. positions in Q1 2017 and 8 closed out, a net change of -6 holders.
- The largest Repros Therapeutics Inc. buyer in Q1 2017 was BlackRock, an estimated $964K added.
- The largest Repros Therapeutics Inc. seller in Q1 2017 was Sphera Funds Management, an estimated $250K sold.
Based on aggregated 13F filings for Q1 2017.